Q1 2023 Earnings Estimate for OPKO Health, Inc. (NASDAQ:OPK) Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK – Get Rating) – HC Wainwright increased their Q1 2023 EPS estimates for shares of OPKO Health in a research note issued on Thursday, March 9th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.02) per share for the quarter, up from their prior estimate of ($0.07). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for OPKO Health’s FY2023 earnings at ($0.22) EPS.

OPKO Health Stock Up 2.5 %

Shares of NASDAQ OPK opened at $1.24 on Monday. The company has a 50 day simple moving average of $1.27 and a 200-day simple moving average of $1.57. The company has a market capitalization of $958.09 million, a P/E ratio of -2.82 and a beta of 1.64. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.85 and a quick ratio of 1.50. OPKO Health has a 1 year low of $1.00 and a 1 year high of $3.78.

OPKO Health (NASDAQ:OPK – Get Rating) last announced its quarterly earnings results on Thursday, February 23rd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). The business had revenue of $185.40 million during the quarter, compared to the consensus estimate of $168.21 million. OPKO Health had a negative net margin of 32.70% and a negative return on equity of 15.77%. The business’s revenue was down 53.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.11) EPS.

Institutional Trading of OPKO Health

A number of large investors have recently made changes to their positions in the company. Humankind Investments LLC purchased a new position in OPKO Health in the 3rd quarter valued at approximately $25,000. Zacks Investment Management acquired a new stake in OPKO Health during the 3rd quarter valued at $25,000. Sax Wealth Advisors LLC acquired a new stake in OPKO Health during the 4th quarter valued at $25,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in OPKO Health by 67.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,083 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 9,308 shares during the last quarter. Finally, Gladius Capital Management LP acquired a new stake in OPKO Health during the 4th quarter valued at $31,000. 23.49% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at OPKO Health

In other news, major shareholder Opko Health, Inc. purchased 14,285,714 shares of the business’s stock in a transaction dated Thursday, January 26th. The stock was acquired at an average price of $0.35 per share, for a total transaction of $4,999,999.90. Following the acquisition, the insider now directly owns 94,285,714 shares of the company’s stock, valued at $32,999,999.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other OPKO Health news, major shareholder Opko Health, Inc. purchased 14,285,714 shares of the firm’s stock in a transaction on Thursday, January 26th. The stock was bought at an average price of $0.35 per share, with a total value of $4,999,999.90. Following the transaction, the insider now directly owns 94,285,714 shares of the company’s stock, valued at approximately $32,999,999.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Phillip Md Et Al Frost purchased 1,000,000 shares of the firm’s stock in a transaction on Wednesday, March 8th. The stock was acquired at an average cost of $1.18 per share, with a total value of $1,180,000.00. Following the transaction, the chief executive officer now directly owns 199,831,694 shares in the company, valued at $235,801,398.92. The disclosure for this purchase can be found here. Insiders own 40.97% of the company’s stock.

OPKO Health Company Profile

(Get Rating)

OPKO Health, Inc is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations.